Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...
The stock's rise snapped a four-day losing streak.
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow ...
In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.
R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.
Nikkei 225 is an index which belongs to the Tokyo Stock Exchange (TSE). The Nihon Keizai Shimbun (Nikkei) calculates the index daily since 1950. The calculation of Nikkei 225 index began on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results